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Cocaine addiction is a widespread psychiatric condition still waiting for approved 
efficacious medications. Previous studies suggested that simultaneous activation of 
nociceptin opioid (NOP) and mu opioid (MOP) receptors could be a successful strategy 
to treat cocaine addiction, but the paucity of molecules co-activating both receptors with 
comparable potency has hampered this line of research. Cebranopadol is a non-selective 
opioid agonist that at nanomolar concentration activates both NOP and MOP receptors 
and that recently reached phase-III clinical trials for cancer pain treatment. Here, we 
tested the effect of cebranopadol on cocaine self-administration (SA) in the rat. We found 
that under a fixed-ratio-5 schedule of reinforcement, cebranopadol (25 and 50 µg/kg) 
decreased cocaine but not saccharin SA, indicating a specific inhibition of psychostim-
ulant consumption. In addition, cebranopadol (50 µg/kg) decreased the motivation for 
cocaine as detected by reduction of the break point measured in a progressive-ratio 
paradigm. Next, we found that cebranopadol retains its effect on cocaine consumption 
throughout a 7-day chronic treatment, suggesting a lack of tolerance development 
toward its effect. Finally, we found that only simultaneous blockade of NOP and MOP 
receptors by concomitant administration of the NOP antagonist SB-612111 (30 mg/kg) 
and naltrexone (2.5 mg/kg) reversed cebranopadol-induced decrease of cocaine SA, 
demonstrating that cebranopadol activates both NOP and classical opioid receptors 
to exert its effect. Our data, together with the fairly advanced clinical development of 
cebranopadol and its good tolerability profile in humans, indicate that cebranopadol is 
an appealing candidate for cocaine addiction treatment.
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inTrODUcTiOn
Cocaine is a widely abused illicit drug with a worldwide prevalence of 0.4%, accounting for 14–20 
million individuals who have used cocaine in their lifetime (1). Cocaine addiction, for which 
approved medications are still needed, causes physical, psychiatric, socioeconomic, and judicial 
problems (2), representing therefore a major social burden. The fourth member of the opioid 
receptor superfamily, the nociceptin opioid (NOP) receptor, is considered a novel potential target 
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for medication of cocaine addiction due to its anti-rewarding 
properties and limited side effects of NOP agonists (3–7).
Nociceptin is the endogenous ligand of the NOP that has been 
proven to inhibit cocaine-induced conditioned place preference 
(CPP) in the rat (8) and NOP knockout (KO) mice showed higher 
cocaine-induced CPP than their wild-type counterparts (9). In 
addition, nociceptin abolished cocaine-elicited psychomotor 
sensitization in wild type but not NOP KO mice (10). Noteworthy, 
intracerebroventricular injection of nociceptin failed to induce 
either place preference or aversion even at a dose as high as 
1,000 ng/rat (11). Consistently, NOP agonists have limited abuse 
liability (12), thus representing promising tools for the treatment 
of cocaine addiction. Yet, direct evidence of the effect of NOP 
agonists on cocaine self-administration (SA) is still lacking.
A growing body of evidence indicates that buprenorphine—an 
NOP receptor and mu opioid (MOP) receptor agonist and kappa 
(KOP) and delta (DOP) opioid receptors antagonist—reduces 
cocaine intake partially via NOP agonism (13). Buprenorphine 
combined with low, but not high, doses of naltrexone, maintained 
its potential to prevent cocaine SA in non-dependent rats (14), 
which could be explained by residual activation of MOP and 
NOP (13). Clinical trials demonstrated that only a high dose of 
buprenorphine (≥16 mg/day) was effective in reducing cocaine 
use, possibly due to simultaneous activation of NOP as MOP was 
fully occupied at this dose (3, 6). Similar results were obtained 
by buprenorphine treatment in alcohol-preferring rats in which 
high doses decreased alcohol intake through NOP activation, but 
low doses increased intake by activating MOP (15) However, the 
limitation of buprenorphine as potential cocaine addiction treat-
ment is owed to its too low affinity to NOP compared with MOP 
(about 50 times lower) (16), and its related abuse liability (17). 
Therefore, we hypothesize that compounds with high affinities 
and strong potency to both NOP and classical opioid receptors 
may have promising potential for treatment of cocaine addiction 
with reduced side effects.
Cebranopadol is a compound already tested in both com-
pleted and ongoing phase-II and phase-III clinical trials for 
pain treatment (11, 18). Radioligand binding data revealed 
sub-nanomolar affinity to both rat and human NOP and MOP 
20 times higher than human DOP and 3–4 times higher than 
human KOP receptors. Cebranopadol is a full agonist for human 
NOP, MOP, and DOP and partial agonist for KOP receptors 
(19). Here, we employed cebranopadol to test our hypothesis. 
In a work concomitantly conducted by others, cebranopadol 
decreased cocaine fixed ratio 1 (FR1) SA in escalated rats and 
reduced cue-induced reinstatement of cocaine seeking (20). 
Here we expanded this investigation by looking at the effect of 
the drug on cocaine reinforcement and motivation by FR5 and 
progressive-ratio (PR) SA. Moreover, to validate cebranopadol 
selectivity for cocaine reinforcement, we tested this compound 
on saccharin SA. Lastly, the NOP antagonist SB-612111 and the 
non-selective opioid antagonist naltrexone were employed to 
determine the pharmacological mechanism by which cebrano-
padol abolishes cocaine consumption. Rats with stable cocaine 
SA baseline were also treated chronically with cebranopadol or 
its vehicle for seven consecutive days to evaluate if the effect of 
cebranopadol is maintained after repeated treatments.
MeThODs anD MaTerials
animals
Male Wistar rats (Charler River, Italy) weighing 270–320 g at the 
beginning of the experiments were used. Animals’ body weight 
at the time of tests was very similar with groups with an indi-
vidual difference not larger than 462.4 ± 8.4. Pairs of rats were 
housed in a room with artificial 12/12 h light/dark cycle (lights 
off at 8.00 a.m.), at constant temperature (20–22°C) and humidity 
(45–55%). Food (4RF18, Mucedola, Settimo Milanese, Italy) and 
water were provided ad libitum except during session time. All 
experiments were conducted during the dark phase of the light/
dark cycle. Rats were allowed to acclimate to the housing room 
for 1 week and were handled three times before any experimental 
manipulation. All procedures were carried out in accordance 
with the recommendations of the European Community Council 
Directive and the National Institutes of Health for the Care and 
Use of Laboratory Animals and were approved by the University 
of Camerino Internal Ethical Committee for the Laboratory 
Animal Protection and Use [(CEAPA) (Protocol no. 3796/12)].
Drugs
Cocaine hydrochloride and morphine hydrochloride (Sigma, 
USA) were dissolved in sterile saline. Saccharin (Sigma, Italy) was 
dissolved in tap water. Cebranopadol (Biochempartner Co., Ltd., 
China) for operant tests was diluted to a fine suspension with 5% 
DMSO and 95% glucose (5%) and administered per os (p.o.) by 
gavage. We chose p.o. administration to mimic the most common 
administration route in human. Cebranopadol for place condi-
tioning was dissolved in 10% DMSO + 5% Cremophor EL + 85% 
saline and administered intraperitoneally (i.p.). For CPP, we used 
the i.p. route to facilitate the rapid absorption of the drug that 
is important to achieve the expression of place conditioning. 
Cebranopadol doses were selected based on previously reported 
p.o. ED50 value. Previous work demonstrated that pharmacologi-
cal efficacy of cebranopadol is maintained for least 9 h (19). The 
selective NOP antagonist SB-612111 was obtained from Tocris 
(USA) and was dissolved in 1-M H3PO4 in distilled water (1:1), 
the opioid receptors antagonist naltrexone (Sigma, USA) was 
dissolved in distilled water. Evidence demonstrates that the doses 
chosen for the two antagonists result in an appropriate brain bio-
availability and significant central nervous system effects (21, 22). 
Pharmacokinetic data on naltrexone and SB-612111 interactions 
are not available.
catheter implantation
Animals were anesthetized by intramuscular injection of 
100–150  µL of a solution containing tiletamine cloridrate 
(58.17 mg/mL) and zolazepam chlorohydrate (57.5 mg/mL). For 
IV surgery, incisions were made to expose the right jugular vein. 
A catheter made from micro-renathane tubing (ID =  0.020′′, 
OD = 0.037′′) was subcutaneously positioned between the vein 
and the back. After insertion into the vein, the proximal end of 
the catheter was anchored to the muscles underlying the vein with 
surgical silk. The distal end of the catheter was attached to a stain-
less steel cannula bent at an angle of 90°. The cannula was inserted 
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into a support made by dental cement on the back of the animals 
and was covered with a plastic cap. Immediately after surgery, 
rats were treated intramuscularly with 200 µL of enrofloxacin 
(50 mg/mL, Baytril, Germany).
Rats were allowed to recover 1  week before SA training. 
Catheters were flushed with 100  μL/rat of heparinized saline 
(20 UI/mL) prior to each SA session, when appropriate 0.5 mg/mL 
of enrofloxacin was added to the flushing solution. Catheter 
patency was confirmed by intravenous injection of 150 μL/rat 
of pentothal sodium (25  mg/mL, Intervet, Italy) at the end of 
experimental procedures.
sa apparatus
The SA stations consisted of operant conditioning chambers 
(Med Associate Inc.) enclosed in sound attenuating and venti-
lated environmental cubicles. Each chamber was equipped with 
two retractable levers located in the front panel of the chamber. 
Before the beginning of the session, an infusion pump delivering 
cocaine was connected by a polyethylene tube to the catheter. The 
infusion pump was activated by responses on the right (active) 
lever, while responses on the left (inactive) lever were recorded 
but did not result in any programmed consequences. Activation 
of the pump resulted in delivery of 0.1  mL of fluid. An IBM 
compatible computer controlled the delivery of cocaine solution 
and recording of the behavioral data.
effect of acute cebranopadol  
on cocaine sa
Fixed Ratio
Rats (n = 8) were initially trained for 2-h daily cocaine SA ses-
sions under FR1 schedule of reinforcement for 10  days, then 
reinforcement schedule was increased to FR5 until stable baseline 
of responding (<10% variation for three consecutive days) was 
reached. Following each cocaine infusion (0.25 mg/0.1-mL intra-
venous), a 20-s time out (TO) period was presented during which 
responses at the active lever had no programmed consequences. 
Cebranopadol (0, 25, 50 µg/kg p.o. 1 h before test) was tested in 
a Latin-square counterbalanced design. At least, a 3-day interval 
during which cocaine SA baseline was reestablished was allowed 
between drug tests.
Progressive Ratio
For PR experiments, a new cohort of rats (n =  8) was trained 
to cocaine SA as described above. After training, the effect of 
cebranopadol on cocaine SA under PR schedule of reinforce-
ment was tested. During PR sessions, the response requirements 
necessary to receive a single cocaine dose increased according to 
the following scale: 5, 11, 18, 26, 35, 45, 56, 68, 82, 98, 116, 136, 
158, 182, 208, 236, 268, and 304. PR session stopped after 6  h 
or if the required ratio was not achieved within 1 h, whichever 
came first. The breakpoint (BP) corresponding to the last ratio 
completed was used as a measure of motivation. One hour before 
test, rats (n = 8) were treated with cebranopadol (0, 25, 50 µg/kg 
p.o.) in a Latin-square counterbalanced design. Drug treatment 
was performed every fourth day. Baseline FR5 cocaine SA was 
reestablished between PR tests.
effect of acute cebranopadol on 
saccharin sa
Another group of rats (n =  8) was used to test the effect of 
cebranopadol on oral saccharin (0.2% w/v) SA. Rats were trained 
to 30-min daily sessions under an FR1 schedule of reinforcement 
until stable lever pressing baseline was reached. At this point, the 
effect of cebranopadol (0, 25, 50 µg/kg p.o.) was tested in a Latin-
square counterbalanced design. Drug treatment was performed 
every fourth day, 1 h before test. Baseline FR1 saccharin SA was 
reestablished between tests. We used FR1 because we expected, 
based on our previous experience, that this schedule of reinforce-
ment would produce in 30 min of saccharin SA—a range of lever 
responses comparable to the initial phase (30–60 min) of cocaine 
SA in FR5.
effect of chronic Treatment with 
cebranopadol on cocaine sa
The effect of repeated cebranopadol administrations was tested 
to evaluate if the effect of the drug on cocaine intake was main-
tained following chronic treatment. For seven consecutive 
days, two groups of rats (n = 7–8/group) with similar cocaine 
SA baseline were treated with cebranopadol (25  µg/kg p.o.) 
or its vehicle given 1  h before initiating the 2-h SA sessions 
under FR5.
effect of sB-612111 and naltrexone  
on cebranopadol-induced inhibition  
of cocaine sa
To explore the mechanisms of action of cebranopadol, we tested 
the effect of the selective NOP antagonist SB-612111 (30 mg/kg 
p.o.), the MOP/KOP/DOP antagonist naltrexone (Nal, 2.5 mg/kg 
i.p.) or their combination on cebranopadol-induced inhibition 
of cocaine SA (23, 24). One hour before session, rats (n =  10) 
received cebranopadol (50 µg/kg p.o.) or its vehicle alone or in 
combination with SB-612111, naltrexone or both antagonists 
together. Rats were subjected to all treatment conditions in a 
Latin-square design. An interval of at least 3 days during which 
cocaine SA baseline was reestablished was allowed between drug 
tests.
cebranopadol-induced Place conditioning
To test whether cebranopadol has rewarding effects per  se, 
we measured the place conditioning induced by the drug in 
a two compartment apparatus using an unbiased schedule of 
conditioning. The first day rats (n = 8/group) were allowed to 
explore the entire apparatus for 15 min (preconditioning) to 
confirm lack of innate preference for one of the two compart-
ments. From the second day, animals underwent one 25-min 
conditioning session per day for 6 days. Cebranopadol groups 
(10 and 50 µg/kg i.p.) received three cebranopadol treatments 
in one compartment or three vehicle treatments in the opposite 
compartment every other day. The control group received 
vehicle injections in both compartments. Treatments were bal-
anced across compartments and days. On the seventh day, drug 
free animals were allowed to explore the entire apparatus for 
FigUre 1 | Effect of cebranopadol on cocaine SA under fixed (a) and progressive (B) ratio of responses. (a) Both doses of cebranopadol decreased the number of 
cocaine infusions earned (top panel); the effect of cebranopadol was specific, as inactive lever responses were not affected by treatments (bottom panel). (B) When 
cebranopadol was tested on motivation for cocaine expressed as breakpoint reached in SA session under a progressive-ratio schedule of reinforcement, the dose 
of 50 µg/kg, but not 25 µg/kg, decreased the break point for cocaine. Values are presented as mean ± SEM. Statistical differences: *p < 0.05 and ***p < 0.001 vs. 
vehicle; #p < 0.05 and ##p < 0.01 vs. 25 µg/kg. SA, self-administration.
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15 min. An operator unaware of treatment conditions recorded 
time spent in each compartment scoring test video clips. A rat 
was considered to have entered a compartment when all its four 
paws stepped inside. Rats received treatments 15 min before 
session.
We treated a group of rats (n = 7) with morphine (5 mg/kg 
i.p.) with the same conditioning schedule as a positive control to 
check whether our protocol is suitable to assess opioid-induced 
place conditioning. Place-conditioning protocol was designed to 
maximize drug effect based on meta-analysis data (25).
statistical analysis
The effect of acute cebranopadol on cocaine and saccharin SA, 
as well as the effect of SB-612111 and naltrexone on cebrano-
padol-induced reduction of cocaine infusions, was analyzed 
by one-way analysis of variance (ANOVA) with treatment as a 
repeated measure. The effect of chronic cebranopadol on cocaine 
SA was analyzed by two-way ANOVA with one factor between 
(treatment) and one factor within (time). Inactive-level responses 
were separately analyzed and used as an additional measure to 
monitor the specificity of drug effects. The Newman–Keuls test 
was used for post hoc analysis when appropriate.
In the CPP experiment, to verify that our protocol was unbi-
ased, we used the t-test for dependent samples to compare the 
time rats spent in each compartment during the preconditioning 
test. For the control group, absence of side preference was tested 
also on the test day.
Preference score was defined as the time spent in the drug-
paired compartment minus the time spent in the vehicle-paired 
compartment. For the control group, which received vehicle 
in both compartments, the “drug-paired compartment” was 
randomly assigned before test. We analyzed morphine place con-
ditioning by t-test for independent groups (vehicle vs. morphine). 
We analyzed cebranopadol place conditioning by one-way 
ANOVA with groups as independent factors (cebranopadol: 
0, 10, and 50 µg/kg).
Results were expressed as mean ± SEM and statistical signifi-
cance was set at p < 0.05.
resUlTs
acute cebranopadol selectively reduced 
cocaine sa
Rats rapidly acquired a stable baseline of cocaine responding 
under FR5 contingency. ANOVA on the effect of cebranopadol on 
cocaine SA revealed an overall effect of doses [F(2, 7) = 43.1069, 
p < 0.00001] (Figure 1A). Post hoc analysis revealed a significant 
decrease in the number of cocaine reinforced responding at 
both doses of cebranopadol tested (p <  0.001). Inactive lever 
pressing was very low and was not affected by drug treatment 
[F(2, 7) = 0.9143, p > 0.05].
When the effect of cebranopadol on motivation for cocaine 
was evaluated under PR contingency, overall ANOVA of the break 
points found an overall effect of doses [F(2, 7) = 6.915, p < 0.01]. 
As shown in Figure  1B, post  hoc tests indicated a significant 
reduction (p < 0.05) of break point following administration of 
the highest dose (50 µg/kg) of the drug.
acute cebranopadol selectively increased 
saccharin sa
Rats rapidly acquired saccharin SA under FR1 contingency. 
ANOVA on the effect of cebranopadol on saccharin SA revealed 
an overall effect of doses [F(2, 7) = 4.859, p < 0.05]. As shown 
in Figure  2, post  hoc analysis showed a significant increase 
(p < 0.05) in saccharin reinforcement earned following adminis-
tration of 25 µg/kg of cebranopadol. At a higher dose (50 µg/kg), 
the drug did not modify saccharin SA. Inactive lever pressing was 
FigUre 2 | Effect of cebranopadol on saccharin SA. The dose of 25 µg/kg, 
but not 50 µg/kg, increased the number of saccharin rewards self-
administered (top panel). Inactive lever response was not affected by 
cebranopadol treatments (bottom panel). Data are presented as 
mean ± SEM. Statistical differences: *p < 0.05 vs. vehicle; #p < 0.05 vs. 25 
µg/kg. SA, self-administration.
FigUre 3 | Chronic cebranopadol treatment on cocaine self-administration. 
Two groups of rats with similar baseline of cocaine intake received 
cebranopadol (25 µg/kg) or its vehicle for seven consecutive sessions.  
The number of cocaine infusions earned by the cebranopadol-treated group 
decreased during treatment in respect to baseline, and returned to 
pretreatment level from the first day posttreatment. In the vehicle-treated 
group, cocaine self-administration remained stable throughout the 
experiment. Data are presented as mean ± SEM and show the last 2 days  
of pretreatment, 7 days of treatment, and 2 days of posttreatment. Statistical 
differences: *p < 0.05, **p < 0.01, and ****p < 0.0001 vs. the last day 
pretreatment.
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very low and was not affected by drug treatment [F(2, 7) = 2.223, 
p = 0.1451].
reduction of cocaine sa Maintained 
Following chronic administration of 
cebranopadol
Analysis of variance of cocaine infusion earned during chronic 
cebranopadol treatment revealed an overall effect of days 
[F(10, 13) = 4.74, p < 0.001], while overall effect of groups was 
not significant [F(1, 13) = 1.00, p = 0.334]. However, there was 
a significant treatment-by-group interaction [F(10, 130) = 4.51, 
p < 0.001]. Post hoc tests indicated that there were no significant 
differences between the first three treatment days and pretreat-
ment SA level, whereas a significant inhibition in the number 
of cocaine reinforced responding was detected from days 4 to 
7 (Figure  3). When treatment was discontinued, cocaine SA 
returned to pretreatment levels. Analysis of the inactive lever 
responding found no effect of group [F(1, 13) = 0.48, p > 0.05], 
days [F(10, 13) =  0.96, p >  0.05], or group-by-day interaction 
[F(10, 130) = 1.42, p > 0.05]. This result seems in part to contrast 
with the effect of acute administration of cebranopadol, where 
the dose of 25 µg/kg reduced cocaine SA. This discrepancy is 
probably due to the different treatment design, Latin-square rota-
tion of each dose in the acute experiment and between subjects 
in the chronic one. To confirm that this apparent discrepancy 
was due to the experimental design, using the t-test analysis for 
dependent samples, we compared the first drug test session with 
the last cocaine-training day. As expected, results showed a sig-
nificant [t(7) = 4.05; p < 0.01] reduction of cocaine SA following 
cebranopadol.
effect of sB-612111 and naltrexone  
on cebranopadol-induced inhibition  
of cocaine sa
To investigate the pharmacological mechanism by which 
cebranopadol inhibits cocaine intake, we tested the effect of 
SB-612111, a selective NOP antagonist, and of the MOP/KOP/
DOP antagonist naltrexone, on cebranopadol-induced inhibi-
tion of cocaine SA. When number of infusions was analyzed, 
ANOVA revealed an overall effect of treatment [F(4, 8) = 8.147, 
p <  0.001]. As shown in Figure  4, Newman–Keuls post  hoc 
test indicated, as expected, that 50 µg/kg cebranopadol sig-
nificantly reduced the number of cocaine reinforced responding 
(p < 0.001). Neither SB-612111 nor naltrexone alone were able 
to antagonize cebranopadol effect. In contrast, when SB-612111 
and naltrexone were coadministered they completely reversed 
cebranopadol-induced reduction of cocaine SA (p  <  0.01). 
Inactive lever responding was very low, and as shown by overall 
ANOVA, was not affected by treatments [F(4, 8)  =  1.152, 
p > 0.05].
cebranopadol not inducing Place 
conditioning
Control rats did not show preference for either of the compart-
ments, demonstrating that place conditioning was performed in 
unbiased conditions [t(8) = 0.44; p = 0.67]. Morphine-treated rats 
FigUre 5 | Effect of cebranopadol on place-conditioning test. Neither of 
the two doses of cebranopadol induced place conditioning, although a 
trend to spend more time in the drug-paired compartment could be 
observed. Inset: morphine induced a clear place preference. Morphine’s 
preference score was 1.7-fold higher than cebranopadol’s. Preference score 
is reported in seconds. Data are presented as mean ± SEM. *p < 0.05 vs. 
control group.
FigUre 4 | Pharmacological mechanism by which cebranopadol decreases 
cocaine self-administration. 50 µg/kg of cebranopadol reduced the number 
of cocaine infusions self-administered. The effect of cebranopadol was 
counteracted by coadministration of the NOP antagonist SB-612111  
(30 mg/kg) and the MOP antagonist naltrexone (2.5 mg/kg) or their vehicles. 
Only simultaneous administration of SB-612111 and naltrexone could fully 
counteract cebranopadol effect and reestablished cocaine intake to control 
level. Neither SB-612111 nor naltrexone given alone altered cebranopadol 
effect (top panel). The effects of treatments were specific for cocaine seeking 
as inactive lever responses were not affected by treatments (bottom panel). 
Administration of vehicle for each compound is indicated by the “–” mark, 
while administration of the active agent is indicated by the “+” mark. Data are 
presented as mean ± SEM. Statistical differences: **p < 0.01 and 
***p < 0.001 vs. control treatment; °°p < 0.01 and °°°p < 0.01 vs. 
cebranopadol + SB-612111 + naltrexone treatment. MOP, mu opioid; NOP, 
nociceptin opioid.
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showed marked development of CPP with a significant preference 
score [t(13) = −2.33; p < 0.05], demonstrating that our protocol 
was suitable to test place preference induced by drugs targeting 
the opioid system (Figure 5 inset). For cebranopadol, ANOVA 
revealed no overall effect of groups [F(2.21) =  1.83; p >  0.05], 
indicating that cebranopadol did not induce significant place-
conditioning effects (Figure 5).
DiscUssiOn
Results showed that cebranopadol significantly reduced cocaine 
SA under fixed and progressive ratio schedule of reinforce-
ments, indicating reduced motivation for cocaine following 
drug treatment. Our data are in good agreement with work 
concomitantly conducted by de Guglielmo et al. (20), showing 
that cebranopadol reduces cocaine SA in rats after escalation 
of cocaine intake in 6-h sessions. The effect of cebranopadol 
was substance-specific because when we tested cebranopadol 
on saccharin SA, we found a slight increase in lever pressing at 
the lowest dose and no changes at the highest dose. A similar 
finding was described by de Guglielmo et al. (20) who attributed 
that using sweet condensed milk as reinforcer demonstrated 
the same behavioral pattern. The tendency of cebranopadol to 
increase the consumption of sweet solutions is consistent with 
its ability to activate MOP receptors. In fact, sweet intake is 
markedly enhanced following activation of this opioid receptor 
by morphine, DAMGO or other selective agonists (26–29). In 
addition, the fact that cebranopadol does not decrease, or even 
increases, responses for natural reinforcers demonstrates that 
the effect on cocaine was not secondary to sedation or to general 
disruption of motor activity. In the chronic study, cebranopadol 
slightly decreased cocaine SA at the beginning of the treatment; 
the effect progressively increased following repeated administra-
tions and became significant after 4 days. This finding supports 
the feasibility of chronic drug administration as a therapeutic 
strategy for cocaine addiction. We also demonstrated that the 
inhibitory effect of cebranopadol on cocaine SA is blocked by 
coadministration of SB-612111 and naltrexone, while com-
pounds alone did not affect the efficacy of cebranopadol. This 
indicates that the effect of cebranopadol on cocaine SA is medi-
ated by two possibly independent mechanisms involving NOP 
and classical opioid receptors. Only simultaneous blockade of 
these two pathways warrants full inhibition of cebranopadol 
effects on cocaine. Finally, in a place-conditioning test, we 
found that in contrast with morphine, cebranopadol did not 
elicit significant expression of place preference, although a 
trend to an effect was detected (30, 31). Additional studies (i.e., 
drug discrimination, operant intravenous SA) will have to be 
carried out to thoroughly evaluate the abuse potential of this 
compound.
Cebranopadol is a high-affinity agonist at both MOP and 
NOP receptors and is almost equipotent in activating both recep-
tors. At higher concentrations, it also activates KOP and DOP 
receptors (19). The pharmacological profile of cebranopadol 
is partially mimicked by buprenorphine, a well-characterized 
compound that acts as a high-affinity partial agonist at MOP 
and low-affinity NOP agonist, but is an antagonist at KOP 
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and DOP receptors (32). Like cebranopadol, buprenorphine 
reduced cocaine intake in the rat (13, 33, 34). This effect was 
confirmed also in rhesus monkeys (35) and in heroin-dependent 
patients co-abusing cocaine (36). Importantly, clinical data 
demonstrated that reduction of cocaine consumption by 
buprenorphine is independent of the effect on heroin intake 
and occurs only at doses higher than 24 mg/kg (36). This dose 
is substantially higher (>16  mg/day) compared with those 
needed to fully occupy MOP, and most likely KOP receptors, 
as the drug shows equivalent affinity for both receptors (32, 
36–39). Based on these receptor affinity profiles, we argued 
that the inhibitory effect of buprenorphine on cocaine con-
sumption was mediated by activation of NOP, which occurs 
at substantially higher drug doses (15, 32, 40, 41). Contrary 
to our expectation, we found that selective blockade of NOP 
did not prevent the effect of buprenorphine. However, the 
effect was fully prevented if NOP and MOP receptors were 
simultaneously blocked (13). Based on this observation, we 
concluded that buprenorphine reduces cocaine consumption 
with mechanisms involving both NOP and MOP receptors. 
Here we demonstrated that, cebranopadol despite acting as a 
KOP and DOP agonist, whereas buprenorphine is an antago-
nist, also attenuated cocaine intake. Based on these data, it 
is tempting to speculate that KOP-dependent mechanisms 
might not be relevant in mediating the effects of these drugs on 
cocaine consumption.
In addition to NOP, MOP, and KOP receptors, although at 
higher concentrations, cebranopadol binds also to DOP (19). 
Based on present results, we cannot fully exclude the possible 
involvement of this opioid receptor subtype in mediating the 
effect of cebranopadol on cocaine. However, this hypothesis is 
discouraged by the lower affinity of this compound for DOP 
and by the fact that psychostimulant consumption is blocked 
by DOP antagonism (42). Cebranopadol is at phase-III stage 
of development for the treatment of pain, and toxicological 
data demonstrated that it is well tolerated in humans (11). 
Its safety profile was confirmed by studies in rodents show-
ing that, contrary to classic opioid analgesics, cebranopadol 
did not produce respiratory depression and impairment of 
motor coordination at pharmacological effective doses (19). 
The opportunity to test this compound in cocaine addicts is 
therefore relatively close.
Theoretically, the ability of cebranopadol to act as KOP ago-
nist could rise concerns on the use of this compound in drug 
addicts. In fact, previous studies have shown that activation 
of KOP receptors is associated with dysphoria, exacerbation 
of anxiety, and enhanced motivation to take drugs of abuse 
(43–50). For instance, it has been shown that activation of 
KOP, recruiting stress response mechanisms, is able to reinstate 
extinguished CPP for cocaine in the rat (51, 52). Moreover, in 
monkeys trained to self-administer cocaine, the administration 
of selective KOP agonists facilitates reinstatement of drug seek-
ing and enhances preference for cocaine if animals are trained to a 
concurrent-choice schedule—choice between food or cocaine 
(45, 53). Here we showed that in the place-conditioning test 
cebranopadol did not evoke aversion and produced a trend to 
a preference probably mediated by its ability to activate MOP 
receptors. Hence, unlike selective KOP agonist, cebranopadol 
appeared to be devoid of negative affective properties in the rat 
(54–58).
Attenuation of drug effect following repeated administra-
tion is always a concern when chronic treatment is required in 
the clinic setting. Interestingly, an earlier study exploring the 
analgesic effect of cebranopadol revealed that the anti-allodynic 
effect of the drug is maintained for substantially longer time 
compared with chronic morphine, which may reflect reduced 
propensity to produce pharmacological tolerance (19). Here, we 
further explored this phenomenon by investigating the effect of 
1-week treatment with crebranopadol on cocaine SA. Results 
demonstrated that the effect improved along the 7 days of drug 
administration, with an important trend toward an increase 
at the end of treatment. Classically, repeated administrations 
of opioid agonists lead to rapid development of tolerance; 
using cebranopadol here this effect did not occur (59, 60). In 
contrast with other opioidergic agents, buprenorphine shows 
reduced propensity to evoke tolerance. For instance, reduction 
of cocaine SA in monkeys was fully retained for a period as long 
as 120 days (35). Based on these observations, it is tempting to 
speculate that the pharmacological profile of cebranopadol—
mimicking buprenorphine properties, but showing even higher 
safety and possibly lower abuse liability profile—may be suitable 
for a chronic therapy in cocaine addicts.
The reasons why molecules with mixed MOP/NOP agonist 
profile have low tendency to produce tolerance remain unclear 
at present and, to some extent, contrast with older data, sug-
gesting that activation of central nociceptin system facilitates 
analgesic tolerance elicited by chronic morphine (61). To 
explain this phenomenon, further studies should analyze the 
molecular mechanisms and, possibly, the intracellular signal-
ing pathways that are engaged when MOP and NOP receptors, 
which are largely co-expressed in the brain, are co-activated 
(62). Interestingly, cebranopadol differently from other agonists 
shows low ability to stimulate the opioid receptors-β-arrestin 
pathway that is typically involved in receptor internalization or 
desensitization (63, 64).
Altogether these results demonstrate that cebranopadol, in 
addition to its already known analgesic profile, shows efficacy 
in attenuating cocaine consumption. This effect is specific 
and does not generalize toward other ingesta (i.e., saccharin). 
Moreover, present findings demonstrate that NOP and classi-
cal opioid receptor pathways are both involved in mediating 
these actions of cebranopadol on cocaine. One limitation of 
the study is that cebranopadol was tested against a fixed dose 
of cocaine. This does not allow to draw conclusions on whether 
the effect of this opioid panagonist depends upon its ability to 
shift the classically U-shaped dose response curve of cocaine 
toward the right (reflecting attenuation of reward) or toward 
the left (reflecting potentiation of reward). In recent years, 
despite significant efforts made to develop new medications 
for the treatment of cocaine addiction, very little is available 
for clinical use. The fairly advanced clinical development of 
cebranopadol makes this compound an ideal candidate for 
an immediate clinical investigation in cocaine-dependent 
patients.
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